Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Govt Must Bolster Leadership in Building Drug Discovery Ecosystem: New Minister
September 26, 2023
- Japan Approves Eisai/Biogen’s Alzheimer’s Drug Leqembi
September 25, 2023
- Japan PM Announces Yen-Loan Program to Fight Pandemics
September 25, 2023
- Ex-Minister Tamura Tapped for No. 2 in LDP Policy Panel
September 25, 2023
- METI to Bankroll 95.5 Billion Yen in 23 Projects to Build Vaccine Sites, Moderna Among Them
September 22, 2023
- MHLW Panel Members Call for Tightening Advertising Regulations for Off-Label GLP-1 Use
September 22, 2023
- Sitagliptin Increases Cancer Risk in 1 in 115,000 People with Current Global Impurity Limit: Makers
September 22, 2023
- Chuikyo Rep Grumbles at Too Many Industry Requests, FPMAJ Chief Wants Health Coverage Dabate
September 21, 2023
- Pharma Groups Stand in Unity to Push Reward for Innovation, Price Maintenance
September 21, 2023
- China to Soon Decide Whether to Arrest Detained Japanese Astellas Employee
September 21, 2023
- Japan Launches Fall COVID-19 Vaccination Campaign
September 21, 2023
- Apply Brand-Based Price Revisions to Qualified Generic Makers: JGA
September 21, 2023
- JPWA Urges Price Hikes for Drugs with NHI Tag Below 20 Yen
September 21, 2023
- MHLW Proposes Curbing Entries of Generic Makers That Threaten Stable Supplies
September 20, 2023
- 10-20% of Infected Adults Suffer Long COVID: MHLW Study
September 20, 2023
- Japan to End Use of Original COVID Vaccine, Previous Omicron Jabs
September 20, 2023
- Hamachi, Miyazaki Named Senior Vice Health Ministers
September 19, 2023
- Health Minister Set to Visit Boston Life Sciences Cluster
September 19, 2023
- Opposition Party Leader Raps Takemi’s Appointment as Health Minister
September 19, 2023
- Japan Grants Orphan Tag to Tafinlar/Mekinist, Retevmo
September 19, 2023
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…